Loading organizations...
§ Private Profile · Palo Alto, CA, USA
Medable is a technology company.
Medable offers a decentralized clinical trial platform to accelerate pharmaceutical research. Its cloud-based technology streamlines study design, patient recruitment, and data management, enabling remote participation and ensuring data quality. The platform integrates AI capabilities, including Agent Studio, to automate processes, enhance efficiency, and provide transparency throughout studies.
Dr. Michelle Longmire founded Medable, motivated by the insight that outdated processes hindered clinical research. Her personal experience with patient access challenges during rare disease research provided the impetus. She established Medable to transform trials through technological innovation, directly addressing obstacles that impede patient access and slow treatment development.
Medable serves pharmaceutical sponsors, emerging biopharma, Contract Research Organizations, research sites, and study participants. The company’s mission is to expedite effective therapies globally. By improving the quality, reach, and speed of clinical research, Medable aims to increase the annual availability of impactful treatments.
Medable has raised $597.0M across 6 funding rounds.
Medable has raised $597.0M in total across 6 funding rounds.
# High-Level Overview
Medable is a SaaS platform company that streamlines clinical trial execution through decentralized trial (DCT) technology and digital health solutions.[1] The company provides an end-to-end, cloud-based platform designed to address systemic inefficiencies in clinical research—including access barriers, outdated technology, and fragmented systems—by enabling remote patient screening, digital consent, electronic clinical outcome assessments (eCOA), telemedicine visits, and real-time data collection.[1][3]
Medable serves mid-to-large pharmaceutical companies, emerging biopharma firms, and contract research organizations (CROs) across therapeutic areas including oncology and vaccines.[1] The platform operates in over 60 countries and supports 120 languages, with access to a global network of over 1 million participants.[5] By automating manual tasks and providing AI-powered analytical insights, Medable accelerates trial timelines and reduces study startup costs—achieving 50% faster study build times with its eCOA+ solution.[5] The company has raised over $500 million and achieved unicorn status in 2021.[9]
# Origin Story
Medable was founded by Dr. Michelle Longmire, who created the company after struggling to access patients in her own clinical research on rare skin diseases.[4] Drawing inspiration from technological innovation in other industries, Longmire rallied stakeholders, partners, and developers to launch Medable with a shared vision of radically increasing the number of effective therapies reaching patients each year.[4] This personal experience with research access challenges directly shaped the company's mission to solve one of healthcare's longest-standing problems: enabling effective therapies to reach people faster.
# Core Differentiators
# Role in the Broader Tech Landscape
Medable is positioned at the intersection of two powerful healthcare trends: the shift toward decentralized clinical trials and the adoption of AI and digital health technologies in drug development.[1][2] As traditional clinical trial models face persistent challenges—geographic barriers, patient access limitations, and slow timelines—DCTs have accelerated in adoption, creating tailwinds for platforms that can digitize and streamline the research process.[1]
The company's timing is strategic. Regulatory bodies increasingly recognize real-world evidence and remote trial designs, while pharmaceutical companies face pressure to reduce time-to-market and development costs. Medable's AI-driven solutions directly address these pressures by automating bottlenecks in clinical development and enabling sponsors to reach previously inaccessible patient populations.[3][4] By standardizing digital trial infrastructure and providing accessible tools to CROs and emerging biopharma, Medable influences how the broader clinical research ecosystem operates—shifting it from fragmented, site-centric models toward integrated, patient-centric digital platforms.
# Quick Take & Future Outlook
Medable's trajectory suggests continued growth as DCT adoption becomes standard rather than exceptional in pharmaceutical development. The company's recent launches—Agent Studio and its Partner Program—indicate a strategic pivot toward automation and democratization, empowering CROs and smaller biopharma firms to conduct digitally enabled trials without building infrastructure from scratch.[4]
However, the company faces headwinds: the DCT market is increasingly crowded with new competitors, and maintaining trial integrity while scaling globally will be critical.[1] Medable's success will likely depend on deepening its AI capabilities, expanding therapeutic area expertise, and strengthening its position as the platform of choice for sponsors seeking to balance speed, cost, and data quality.
The broader implication is that Medable is helping reshape clinical research from a geographically constrained, time-intensive process into a globally accessible, technology-enabled one—fundamentally changing how quickly new medicines reach patients.
Medable has raised $597.0M across 6 funding rounds. Most recently, it raised $300.0M Series D in October 2021.
Medable has raised $597.0M in total across 6 funding rounds.
Medable's investors include Jeffrey B. Kindler, Tiger Global, Bain Capital Ventures, Citi Ventures, Davidovs VC, GSR Ventures, Primary Venture Partners, Sapphire Ventures, Western Technology Investment, David Hartwig, Tina Hoang-To, Anna Long.